Guidelines for prostate specific antigen (PSA) testing in Australia recommend that men at average risk of prostate cancer who have been informed of the benefits and harms, and who decide to undergo regular testing, should be offered testing every 2 years from 50 to 69 years. This [...]
Internationally, screening programmes and clinical practice guidelines recommend when older adults should stop cancer screening using upper age limits, but it is unknown how older adults view these recommendations. The obective of this study is to examine older adults’ views and experiences about continuing or [...]
Guidelines for prostate specific antigen (PSA) testing in Australia recommend that men at average risk of prostate cancer who have been informed of the benefits and harms, and who decide to undergo regular testing, should be offered testing every 2 years from 50 to 69 years. This [...]
Primary care practitioners (PCPs) play a key role in cancer screening decisions for older adults (≥ 65 years), but recommendations vary by cancer type and jurisdiction. The purpose of this study is to examine the factors influencing PCPs’ recommendations for breast, cervical, prostate, and colorectal cancer [...]
Deciding whether it is worthwhile to advise older adults (aged ≥ 65 years) to continue or stop cancer screening is not straightforward for primary care practitioners (PCPs). At a population level, there is evidence that the benefit/harm trade-off of cancer screening becomes less favorable in older adults. The [...]
Since 2020, hundreds of thousands of more deaths than expected have been observed across the globe. Amid the coronavirus 2019 (COVID-19) pandemic, current research priorities are to control the spread of infection and minimise loss of life. However, there may be future opportunities to learn [...]
This review found robust evidence to inform discussion of possible recalibration of diagnostic thresholds, or use of alternative labels, for low-risk prostate cancer. RCTs and cohort studies demonstrate that active surveillance is a safe option for very low-risk and low-risk prostate cancers, with extremely low [...]
Most patient decision aids for prostate cancer screening lacked important information on overdiagnosis. Specific guidance is needed on how to communicate the risks of overdiagnosis in decision aids, including appropriate content, terminology and graphical display.
The aim of this systematic review and meta-analysis was to describe and quantify socioeconomic differences in use of prostate cancer treatment in the literature.
Population trends in PSA testing and prostate cancer incidence do not perfectly correspond. We aimed to better understand relationships between trends in PSA testing, prostate cancer incidence and mortality in Australia and factors that influence them.